A combination of Mirati Therapeutics Inc.’s genetic mutation-targeting adagrasib and Eli Lilly and Co.’s older cancer drug Erbitux shrank tumors in 39 percent of patients with advanced colorectal cancer treated in a small trial, the company said on Sept. 19.

An experimental Amgen Inc. drug that targets a specific genetic mutation shrank tumors in 32% of advanced lung cancer patients and 7% of those with colon cancer, according to data from an early-stage trial.

Working with a new class of drugs called G12C KRAS inhibitors, the Francis Crick Institute and Institute of Cancer Research developed product combos to stay ahead of drug-resistant tumors.